
## **Ruth Eichner**

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6431277/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	MCT1 is a predictive marker for lenalidomide maintenance therapy in multiple myeloma. Blood Advances, 2022, 6, 515-520.	5.2	5
2	The IMiD target CRBN determines HSP90 activity toward transmembrane proteins essential in multiple myeloma. Molecular Cell, 2021, 81, 1170-1186.e10.	9.7	39
3	Treatment Guided By Next Generation Functional Drug Screening Provides Clinical Benefit in Advanced Aggressive Hematological Malignancies: Final Evaluation of the Open Label, Single Arm Exalt Trial. Blood, 2020, 136, 2-4.	1.4	1
4	Cross Talk Networks of Mammalian Target of Rapamycin Signaling With the Ubiquitin Proteasome System and Their Clinical Implications in Multiple Myeloma. International Review of Cell and Molecular Biology, 2019, 343, 219-297.	3.2	16
5	MCT1 As Molecularly Validated Predictive Marker for Lenalidomide-Maintenance Therapy in Multiple Myeloma. Blood, 2019, 134, 3187-3187.	1.4	1
6	The IMiD-Target Cereblon Determines Transmembrane Protein Quality Control Promoting Tumor Metabolism. Blood, 2019, 134, 314-314.	1.4	0
7	Immunomodulatory drugs disrupt the cereblon–CD147–MCT1 axis to exert antitumor activity and teratogenicity. Nature Medicine, 2016, 22, 735-743.	30.7	145